GLA is associated with ESCC progression and chemotherapy response via DNA damage repair–related pathways
By
Ke Chen
Qinsong Yang
Chen Fang
Weiran Zhang
Yu Feng
Haitao Ma
July 15, 2026
Clinical Scorecard: The Role of GLA in the Progression of ESCC and Its Impact on Chemotherapy Efficacy Through DNA Repair Mechanisms
At a Glance
Category Detail
Condition Esophageal squamous cell carcinoma (ESCC) Key Mechanisms DNA damage repair and chemoresistance Target Population Patients with esophageal squamous cell carcinoma Care Setting Oncology clinical management
Key Highlights
GLA is significantly upregulated in ESCC and associated with poor prognosis. High GLA expression correlates with DNA damage repair and chemotherapy resistance. GLA knockdown enhances sensitivity to gemcitabine and cisplatin. Migalastat combined with chemotherapy shows potential for increased cytotoxicity. GLA serves as a novel diagnostic and therapeutic target in ESCC. Guideline-Based Recommendations
Diagnosis
GLA expression can be used as a diagnostic marker for ESCC. Management
Consider GLA as a therapeutic target to overcome chemoresistance in ESCC. Monitoring & Follow-up
Monitor GLA levels to assess treatment response and prognosis. Risks
High GLA expression may indicate a risk of chemoresistance in ESCC. Patient & Prescribing Data
Patients with unresectable or locally advanced ESCC
Combination of Migalastat with gemcitabine or cisplatin may enhance treatment efficacy.
Clinical Best Practices
Incorporate GLA expression analysis in the diagnostic workup for ESCC. Evaluate the potential of GLA-targeted therapies in clinical trials. Related Resources & Content
